WO2010113022A1 - プラスミノーゲンアクチベーターインヒビター-1阻害剤 - Google Patents
プラスミノーゲンアクチベーターインヒビター-1阻害剤 Download PDFInfo
- Publication number
- WO2010113022A1 WO2010113022A1 PCT/IB2010/000731 IB2010000731W WO2010113022A1 WO 2010113022 A1 WO2010113022 A1 WO 2010113022A1 IB 2010000731 W IB2010000731 W IB 2010000731W WO 2010113022 A1 WO2010113022 A1 WO 2010113022A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- benzoic acid
- aki
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel compound having a plasmonage activator (below, also referred to as PA), and P containing the compound as an active ingredient. Further, the present invention relates to an effective ingredient for treating various diseases related to the onset of P, comprising the above compound having P harmful activity as an active ingredient.
- the ring must be capable of transporting oxygen to the tissue and recovering unwanted materials, but it must also stop bleeding and prevent loss. It is thought that when a function that is incompatible with this mobility is tilted as an alarm, blood and plugs are generated in the blood vessel, resulting in a blood vessel.
- a plasmon actuator (hereinafter referred to as P) is activated by converting the plasmonage to a plus.
- the plasma activator P) inhibits P.
- Plasnoge Actuator converts a Plasnoge that is a plus into a plus. Plus breaks down and turns it into a thing.
- u P Naze plasto noge activator
- P has a sex form (ac ve o) that shows P harmful activity and a latent a en o) that does not show P activity due to its three-dimensional structure.
- ac ve o sex form
- a latent a en o sex form
- 20 PA is present in plasma and is known to be produced by the major vascular endothelium, liver, (egaka yocy e), and so on.
- P is an acute protein that is produced by a cytokai proliferator and is considered to be the cause of harm in the septic tuberculosis group (D).
- D septic tuberculosis group
- urinary disease As for urinary disease, the progression and complications of arteriosclerosis are considered to be the cause of urinary disease and morbidity, which is a major complication of urine disease.
- urine disease the addition and interrogation are characteristic, and the appearance of P in the body and ducts is enhanced.
- P addition of P is observed under hyperglycemic conditions. Also, in experiments using Deus, it was confirmed that it was a P-expressing quiz (2).
- P endothelium formation and intogenesis It is also thought to be related to the control that is considered to be involved in (8-2). For this reason, it inhibits P sex, including thrombus, urine disease and urinary complications, various diseases, diseases such as glaucoma, multimodality, alopecia, bone marrow, blood, and aids (idea) And is useful as a disease of and atherosclerosis (22).
- vascularization in the P membrane is promoted by non-4, and it is considered useful for the treatment of P, retinal, and other diseases caused by vascularization.
- n f2 John Schoenhade a P as no enac va o nhb o has a c cad an hyhm nb nd ndvda s T omb aemo 2007 98 47948
- a substrate is required for a compound that can be produced in large quantities and is low in safety.
- a substrate is required for a compound that can be produced in large quantities and is low in safety.
- effective products that fundamentally improve the treatment of tissues.
- Urinary disease C Urinary disease C
- harm flame and other diseases
- glaucoma Urinary disease C
- Inhibiting P focusing on P, which is involved in the development and development of various states of disease, multimodality, radiation damage, alopecia), bone marrow, obesity, aids, atui, and atherosclerosis
- Anti-urinary and urinary complications which are safe drugs with active ingredients that can be produced in large quantities, especially as antithrombotic and antithrombotic agents Remedies, urinary remedies, (C) remedies,
- Therapeutic medicine glaucoma therapeutic medicine, multi-modality medicine, anti-radiation alopecia), therapeutic medicine, liver medicine, bone marrow, anti-anti-aid, anti-cardiosclerosis To do.
- P has already had results such as pulmonary disease, as well as illnesses such as cancer, urine disease, urinary complications, diseases such as urinary disease and glaucoma, various Urinary disease, Chronic C), Ze group, Harm,), Symptom group, Radiation harm, Alopecia (), Bone marrow, Obesity, Aids, Arteriosclerosis It is known that there is. It has also been suggested that P agent is useful as a therapeutic agent for sweet illness, which is thought to develop in the brain. Therefore, the compound (1) is more useful as the P, and can significantly improve the organization based on the P harmful activity. It may be possible to prevent or improve the disease.
- hydrogen atom, gene, ⁇ 6 aki, C3-6 quake, C3-8 quaki-6 aki, 3-8 qua, 2-6 aki, 3 ⁇ 8 aku 2-6 aki may have substitution, or may have substitution, X is a child, or CC
- O may have a substitution
- -R is the same or different and represents a hydrogen atom, optionally substituted to 6 alkyl, or C.
- Ding may have single bonds, substitutions ⁇ 3 alkylene atoms,
- D may be substituted aryl aryl may be substituted or aryl substituted C3 to cycloalkyl or rocycloalkyl may be substituted C3 to 8 V chloro or rocycloa or Means damantyl group
- “Inside” may have a substitution ⁇ 6 Alky N ⁇ And ⁇ When Ding is a single bond, D is not a Fe with no. ,
- ⁇ V R is a hydrogen atom or a hydrogen atom, is an elementary atom 1-6 alkyl, or ⁇ 6 cycloalkyl, is a single bond, or
- Alkylene ⁇ A may have ⁇ Aryl means allyl. Is when R is a hydrogen atom. . ⁇ Indicated by (c)
- Y represents a child or oxygen atom
- A is as defined above
- G represents a hydrogen atom or a 6 alkyl group.
- R represents a group which is bonded to a hydrogen atom or an alkylene group to form a 3-8 cycloalkane. May be substituted, substituted, or substituted with 6 to 6 aki (the aki ring may form a quack ring) or substituted with 1 to 6 Aquiaki's elementary atom may form a quack ring) or may have a substitution 6 Aki CO (AkiVIIC0, Aki group has its elementary atom's part It may have a quake ring), or it may have a substitution.
- ⁇ 6 aki (Aki ⁇ , the aki group has a quake ring formed by its elementary atoms. ), May have C2 ⁇ 6, may have substitution C2 ⁇ 6 Aki CO O, in which case is a grave, Is a nigga group. ), Four
- A is a group represented by).
- C to 6 Aki 4 (in this case, is a group).
- Adachi or the following formula (X)
- CH may have, part may form a cycloalkyl group, and may be substituted on an elementary atom. Is the number of O or, is the number of to, B is C R
- the compound represented by) is generally the compound represented by (a), or a compound described in
- the compound represented by a) is a compound represented by the following formulas (a) to (a4):
- R to R. , X, and D are the above.
- R-R. , X, T, D are the above. May have a substituent.
- R to R. x,, D are as described above.
- Means an optionally substituted 6-6 alkylene, 2-6 alkylene, or C 2-6 alkylene group.
- R to R. ,, X,, D are as defined above.
- CH. May have a substitution on the carbon atom. •
- the capital may form a cycloalkyl group. Is the number of O or, and is the number of O ⁇ .
- G is the compound described in (1), wherein the compound represented by 7) 1) is a compound represented by general (e), or a compound thereof
- R R, and x are the compounds described in (1), wherein the compound represented by 8) (1) is a fluoro group, or a compound thereof.
- Compound (1 is at least a compound selected from the group consisting of the compounds of Implementations 7 to 7 described in 2, (1 1) (19) The compound described in any of the above, or a compound thereof.
- Rr ⁇ R, x ⁇ and A are the same as above.
- Is converted to a hydrogen atom in a living organism ⁇ 6 alkyl CH (R) CR or CH (R) CR represented by R is a hydrogen atom or ⁇ 6 alkyl, R is ⁇ 6 alkyl or 3-6 cycloalkyl, or 5 alkyl 2 as shown in formula X 3
- Solen 4 yl Indicates a methyl group.
- R 1, A,, and x are the same as above.
- R, R A ⁇ , and x are the same as above.
- Step 3 reacting to produce compound (6) having 4,5 5 4 1,2 4 Asiazo 3a group
- R 1, R 2, D and x are the same as above.
- A represents when W of the group represented by the following formula XV is a group substituted with D Ta D Tb, or W of the group represented by the following formula XV XV or X is a group substituted with D Ta.
- a is Stealth C. Or represents an ano group.
- AW is Logen or is represented by the following formula XV or XV having a trifluoromethanesoxy group.
- Ta represents a single bond or an alkyl having a prime number to 3; T represents an alkyl with a triplet at the tip and M represents (R ) RR represents a hydrogen atom or an alkyl group, and in the case of an alkyl group, an R group may be bonded to form a ring.
- Z V Z is • V is a rogen. Indicates.
- Rr, x, R and A are the same as above.
- b represents a steal C log iodo or ano group.
- R is elimination, a is optionally substituted, and alkylene alkylene having a number of from to may represent the capital of each of the alkylene atoms forming a cycloalkyl ring.
- a method for producing a compound (4) or a compound (5) represented by a general formula () (4) or a compound (5) (9) Generating a process,
- R, x,, b and A are the same as above.
- P represents an protecting group for an ano group. 21.
- R is D Ta
- R represents an alkyl, aryl, aralkyl, or hydrogen atom.
- A is the same as in 2 8) 2 9)
- R A a ⁇ “a x, R” and. Is the same as above.
- R. Is an alkyl aryl, or aralkyl is optionally substituted
- the compound (3) is produced by reacting the compound (42) represented by the formula (a) in which the part of the elementary atom of alkylene may form a cycloalkyl ring with the compound (42).
- P 1 is related to the disease, thrombus in arteries, in veins Surgical vein (DT), Seeding tube (DC), urinary complications (major harm, small) (urinary disease) or (urinary disease), after arterial (PT), urinary disease Glaucoma disease, ((CKD), z
- the medicine according to 42 which is harm,), symptom group, radiation harm, alopecia), bone marrow life, obesity, aids, arteriosclerosis or atiosis.
- Thrombus in the pulse Thrombus in the pulse, Thrombus in the brain, ie (Thrombus, Brain, Transient, Thrombus in the heart (heart disease, Myocardium), Thrombus in the lower limb (
- P Effectiveness with noxious activity includes compounds described in 0) (including compounds described in ()) If, or these, are pharmacologically tolerated, or are associated with P Ru
- the prevention or prevention of the disease including administration to a patient who may be.
- P1 is associated with thrombosis, arterial thrombus, vein thrombosis, surgical vein (DT), seed tube (DC), urinary complications (major harm, small) (Urinary disease) or urinary disease), arterial PTC) after re-, urinary disease, green disease, ((), zest group, harm,), group, radiation harm, alopecia (),, Bone marrow, 5.
- the method according to 5), wherein the disease is atherosclerosis or atiosis.
- Thrombus in pulse Thrombus in brain, Thrombus, Brain, Transient
- Thrombus in heart Heart disease, Myocardium
- Thrombus in lower limb Thrombus in lower limb
- a tube () and a thrombus in a pulse Or a tube () and a thrombus in a pulse, a thrombus that occurs in a limb (partial vein), or a thrombus that jumps into the lung), (52).
- P1 is related to thrombosis, arterial thrombus, venous blood plug Surgical vein (DT), seed tube (D), urinary complications (major harm, small) (Urinary disease) if (urinary disease), arteries (re-post-PTC, urine disease, green disease, (C), zebra group, harm,), syndrome, radiation harm, alopecia),
- Thrombus in pulse Thrombus in brain (Thrombus, Brain, Transient), Thrombus in heart, Cardiomyopathy, Myocardium, Thrombus in lower limb (
- a tube (), a thrombus in the pulse, a thrombus in the limb (partial vein), or a thrombus that jumps into the lung), or the compound described in (62).
- a new compound having high utility for P can be provided. Is a prophylactic against various conditions caused by P Or, it is useful as a pharmaceutical active ingredient such as an agent.
- a pharmaceutical comprising a compound capable of mass production as an active ingredient.
- (P) having high use for P is an active ingredient, it can be effectively used as or for various diseases caused by P 1 property.
- P thrombus in an artery
- a thrombus in a vein a surgical partial vein DT
- an inoculation tube intestine group an inoculation tube intestine group
- Akira's target is the one shown in (1) below.
- hydrogen atom, atom, ⁇ 6 aki, C3-8 quaki, C3 8 quaki-6 aki, C3 8 qua, C2-6 aki, C3-8 alk C2-6 aki, ants having or without substitution, and 5 to 6 having or without substitution may be mentioned. More preferably, a hydrogen atom, a geite, ⁇ 6 aki, or 2 having or not having 2, or 5 having an ant having 2 or not having 2. , And are not hydrogen atoms at the same time. More preferably, and R 2 is a hydrogen atom, and the other is an ant having or not having a gate, or 5 ants.
- R 1 and R 2 may be the same or different and each represents a hydrogen atom, a prime number having 6 to 6 substituents, an unsubstituted group, or C. When is 0, R and R cannot be hydrogen at the same time. It is also preferred that when R and R are hydrogen atoms at the same time, or one is a hydrogen atom. Also, when and R is a group other than a hydrogen atom, is preferably 0.
- Quaki with prime 3-8 with or without ants A quasi having a prime of 3 to 8 or having a prime of 3 to 8 means a prime of 3 to 8 quas or a niche group. Preference is given to or having an aryl group with or without two.
- To (V) represent 0 or a number, and when R described later is a hydrogen atom. ).
- R means a hydrogen atom or a genome. It is preferable that R is a R atom when, and R is a hydrogen atom when is.
- R means a hydrogen atom, an aki with 6 to 6 carbon atoms, or an aki tomb with 1 to 6 primes. It is preferably a hydrogen atom or an aki group having a prime number of 6.
- E means a glove or an aki group. It is a good idea.
- Ng Bond or Akin Tomb It is a gong bond.
- G means a hydrogen atom or an alk group having a prime number of 6; M is a hydrogen atom.
- R are simultaneously a hydrogen atom or an alkyl group which is bonded to form 3 to 8 quaca.
- R R is a hydrogen atom at the same time, the below-described is a group having 2 to 6 primes having or not having a substituent.
- R R is preferably a hydrogen atom or an alkyl group which is bonded to form a oxa.
- the aki group may form a quake group), the substituted or unsubstantiated number of aki CO aki CO, the aki group is the qua group. It may form an Aki group. ), With or without substitution, prime to -6 aki or aki groups may have a grave tomb. ), With or without substitution 2 to 6 primes, with or without substitution 2 to 6 primes, CO CO 4, 4 to 6 carbons with 4 substitutions, adatin,
- CH. May have a substitution on the elementary atom, and the part may form a cycloalkyl group. Is the number of O or, is of O ⁇ .
- ring board has or has a prime number of 2 to 6 aki, or has or has a prime number of 6 aki or has a 2 or has a prime number of 2 to 6's
- the compound () is bo, in which X is a group, or its physical properties.
- R in COOR is a hydrogen atom or an Achia, Araki CRO COR, or CR) O CO OR that is converted into a hydrogen atom or a hydrogen atom in a living organism.
- R represents a hydrogen atom or a prime number to 6 aki
- R represents an aki group having a prime number to 6 or a quack group having a prime number of 3 to 8.
- each ⁇ 6 G means grave.
- a hydrogen atom is preferable. Examples of the above include groups represented by deviations of the following formulas (X 1) to (X 3).
- B is CO (R in COOR is a hydrogen atom, or a complex represented by the formula (). Below, examples of these symbols and examples thereof will be described.
- R to R R R 2 G in the bright compound usually a prime number of 6 or the like key group can be mentioned.
- key groups include: Methi, Chi, Pippopuchi, s Chi, Chi, Chimechi, Tet, 3 Mechi, Mechipi, 2 Mepipi, 2 2 Mepipipi
- Mechipechi Mechipechi, 2 Mechipechi, 3 Mechipechi, 4 Mechichi, Mechichi,, 2 Mechichi,, 3 Mechi, 2 2 Mechichi, 2 3 Mechichi, 3 3 Mechichi
- H 2, 2 2, 2 2, 2 2, and 2 2 groups are included. More preferred is a quaternary group having 4 to 4 primes, such as methic, propiopopic, and thio, more preferably meth and thio, particularly preferably meth.
- the key represented by R may have a substitution.
- examples thereof include a genus, a carbon number of up to 6 carbon atoms replaced with a carbon number of up to 6 carbon atoms, a hydroxyl group, CCCCC, a force group, and a carbo group.
- examples of the key of the key and the key include a hydroxyl group substituted with a group having 6 to 6 carbon atoms, preferably a group having 4 to 4 carbon atoms.
- the aki represented by or includes an aki described above, and a C 3 -like aki group.
- Preferred examples of the vacant space include a thio group.
- the aralkyl represented by RR or, or the quack formed by the carbon group of the aki group is usually a prime number of 3 to 8, preferably a prime number of 3 to 6. More preferred is a prime number 5 or 6 aki group.
- These quark groups include cuppi, cuticle, cupecchi, cucumber, cuticle, cuckoo groups and the like.
- the quake formed by the aki carbon atom of quaki may have a 2 or 2 at any position.
- gexy, C 4 -C 4, C 4 -C 4, C 4 -C 4, C 4 -C 4, hydroxyl, CCO, CCC, ano, strength, A carbo group can be mentioned.
- Aki and Akabo Aki are as described above.
- Examples of quats shown in the light compounds include 3 to 8 quake groups having the same, different, or multiple children selected from the group consisting of a nitrogen atom, an oxygen atom and a child. be able to. Physically, for example, Oki (, 2 Oki), Aze (, 2), Oki (, 2, 3), Chi (, 2, 3 Chita), Rigid (, Di, 2 Rigid), Tetradoff (, Tetradra 2 i, tetradra 3 i),
- the group can be mentioned.
- the quake group may have either or 2 at the same position as the above quaki.
- the position of the quake group can be cited in the same way.
- 3 to 8 aki to 6 aki represented by R to 3 to 8 carbon atoms, preferably 3 to 6 prime atoms, more preferably 5 or 6 prime atoms.
- the number of carbon atoms in the aki group is preferably ⁇ 4, more preferably ⁇ 2.
- These cucumber groups include cuppimechi, cupupichi, kuchimechi, kuchi, kuchimechi, kupetsuchi, kumechi, kuchi, kuchimechi, kuchi, kuku This includes Ochimechi and Quochi groups.
- a qua shown by R ⁇ means that the above quake group has the above two bonds, in other words, a double number ⁇ 2 and a prime number of 3-8. It is a group. More preferably, the prime number 3 6 is preferably a prime number 5 or 6 5 or 6).
- a double group is a prime number 5 or 6, and a more preferred group is a group.
- the above-mentioned cure group carbon atom or 2 is replaced by the same or different atom selected from the group consisting of nitrogen atom, oxygen atom and child.
- it is a group formed by substituting a carbon atom with a prime atom in a 5 or 6 prime group that forms a double bond, more preferably a qua group.
- the quo and quo shown in have a or 2 in any position.
- Aki and Akaboaki are described above.
- Examples of the alkyl represented by R ⁇ in the light compound include a prime number 2-6 alkyl group having a triple bond. Specific examples of the alkyl group include thio, puppies, 2, 3, methyl 2-puppies, 2-inch, and 2 groups. Is better.
- C3-8 quay 2-6 aki represented by R ⁇ in the bright compound has 3 to 8 carbon atoms, preferably 3 to 6 primes, more preferably 5 or 6 quakes.
- Examples thereof include an alkyl group having a prime number of 2 to 6 and having a key group as a substituent.
- the carbon number of the aki group is preferably 2 to 3, and more preferably 2.
- These quakiaki groups include cuppi, ku, cupenti, ku, ku, kuo groups and the like.
- the following groups include:, h, ant, nat, and
- ant group examples include a group having a substitution.
- Prime number ⁇ 6 Aki (preferably prime number ⁇ 4 Aki), carbon number ⁇ 6 Aki, carbon number ⁇ 6 Aki (preferably prime number ⁇ 4 Aki), carbon number ⁇ 6 Aki , C 6 -C 6, hydroxy, CCO, CCC, ano, force, azo, zoi, and groups.
- quakis include aki groups having 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, and more preferably 4 to 5 carbon atoms. Included in the quaki group include cupupioki, kuoki, kuchioki, kuoki, kuoki, kuoki group.
- the light compound as represented by and, and 3 or 6 having the same or different or a plurality of children selected from the group consisting of a nitrogen atom, an oxygen atom and a child, preferably 5 Up to 6 groups can be listed. Physically, for example, saturates such as fu, chi, pirari,, oki, iso, thiary, iso, okiri, thiadia, triazo, tetra, pyridi, pyri, bi, and etc. .
- the group has the following properties: Ge, Aki having 6 to 6 carbon atoms (preferably prime having 4 to 4 primes), 3 to 8 carbon atoms, C6 to 6 carbons, Aki having 4 primes ), 3 to 8 carbon atoms, C 6 to carbon atoms, hydroxyl group, CCO, CCC, a, force, acabo, zoi, and oxime groups.
- the phosoxy group is a group having a group or a group which is substituted at that position, and is desorbed in a living body or converted into a group, and exhibits P property. Yes, you can drag.
- Examples of the zea shown in the light compound include a group formed by condensing ze and the above. Specific examples include id, isoid, la,, ri, zo, ri, isoli,, sa, li, asia.
- the above-mentioned zone may have up to 3 positions at any position.
- Ge C 4 -C 4, C 4 -C 4, C 4 -C 4, C 4 -C 4, hydroxy, CCCC, A (preferably)
- Examples thereof include gears, ano groups, force groups, and carbo groups having an alk group having 4 to 4 carbon atoms.
- Aki, Aki, and Ali are the descriptions of Aki, Aki, and Ali.
- the aki group may be a prime group having a prime number of 6 to 6, particularly preferably -4 or in the form of an aki group.
- Aki group has meth,,. H, ppi, tochi, 2 h,
- aki, aki and aki in akiaki C include cases where the aki atoms are combined to form a prime 3 to 8 quake).
- qualifiers include cups, cupters, kuta, and cupas, kupta, and kocta.
- Examples of a shown in the light compound include a prime number 26 or a group having a double number of ⁇ 3.
- groups include bi, methyl, pepe, ten, 2, te, and 2 te groups. It is a bin group.
- alkyl group shown in the light compound examples include a prime number 2 to 6 which forms a triple bond, or a ring-shaped alkyl group. Crying, chi, puppy, meppin,, 2, mechi, 2 mechi, akin H, 2 peti groups are included.
- CO, A, and Aki may have either or two.
- Ge 4 carbon atoms, 4 to 4 carbon atoms, hydroxyl group, C, CC, CC, ano, force, acabo, ano, ano, dioxoboa (BzVII), acaboano (e.g., tokiboano (BocVII), metokiboano, tokiboano, poppoboano, isoppoboboano, And the like, and the like.
- BzVII dioxoboa
- acaboano e.g., tokiboano (BocVII)
- Aki as described above.
- Examples of the aki shown in the light compound (1) and the aki in the aki shown in Fig. 1 may include a prime or three or other aki group.
- Achi groups include meth, thio, propyl and tochi groups. More preferred are Chi, Chi, and Tochi groups.
- examples of atoms include atoms, chlorine atoms, elementary atoms, and atoms. It is an elementary atom, an elementary atom, an atom, and more preferably an elementary atom.
- the groups represented by () and may have up to 2 positions at any position.
- Ge carbon atoms of up to 4 carbon atoms, carbon atoms of up to 4 carbon atoms, carbon atoms of up to 4 carbon atoms, carbon atoms of up to 4 carbon atoms, hydroxyl groups, C, COCOCC, , Gears, ano, force, carbo groups having aki having 4 to 4 carbon atoms, and the like.
- Aki, Aki, A are as described above. Is the basis.
- Aki Aoki or Araki Oki Cabo that can be converted to a key group when collected, (2) A group that can be easily converted to a power group, and (3) Key and biological, etc. Examples include groups that are recognized as groups.
- 1 akabo, aokikabo, and arachiokabobo are groups represented by CR, and each R is a group having a prime number of 6, an a (preferably And a group which is arachi (or di).
- (2) is a group represented by CR, and is a (5 key 2 ox 3 s o 4) meth group represented by the following formula:
- R represents an alkyl group of prime number
- the compound (1) having a biological group such as (B) and the biological group may be referred to as the biological 20 of boric acid.
- the compounds 1) targeted by Ming include preferably those represented by the following formulas or biological compounds of complex and boric acid.
- the clear compounds 1) can be divided into the following groups (a) to 9) according to the type of substitution.
- R R. D is a compound in which the above is a group represented by the following formulas:
- R R is as described above.
- f) is a compound that is a tomb
- the compound () belonging to can be represented by the following formula or complex and its physical properties.
- the compound a) can be further classified into the following a) to a 5) according to the category.
- (a4) is a compound represented by CO 2 CO 3, which may have a substituent ⁇ 6 aki, which may have a substituent ⁇ 6 aki CO 2, or a formula
- the compound (a) includes the above-mentioned a), bo whose X is (C C) and its physical properties, and its complex child and its physical properties.
- B is the basis of X and X.
- X is a group
- B is present at the ot position of the above-mentioned zeal ring
- R is present at the meta and la positions, respectively.
- R is R 3 at position 3, B and 4 and 5 of the above o-ring.
- R and R are the same as above, but preferably the same or different, hydrogen Atom, Ge, C3-8 quaki, 3-8 quake-6 aki, 3-8 quaki C2 6 aki, -8 qua, C2-6 aki . More preferably, R located in the meta position is a hydrogen atom, and R located in the la position is a genus, ⁇ 8 quaki, 3 8 quaki C ⁇ aki, C3-8 quaki C2 Deviation of ⁇ 6 aki, 3-8 qua, or 2-6 aki. R is located in the La position, and is preferably a gutta.
- the preferred atoms are elementary atoms and atoms, and the more preferred are elementary atoms.
- the quaki of the prime number 3 to 8 the quaternary group is preferred.
- the quaternary group is preferred.
- the quaternary group is preferred.
- the quaternary group is preferred.
- the quaternary group is preferred.
- the quaternary group is preferred.
- the quaternary group is preferred.
- 3 to 8 aki to 6 aki preferred are prime to 6 aki having a cu group as a substitution, and more preferred is a prime 4 aki group having a qu group as a substitution.
- C3 to 8 aki 2 to 6 aki preferably 2 to 6 primes having a qua group as a substituent, more preferably 2 to 3 primes having a qua group as a substitution It is a group.
- preference is given to cubyl groups, and more preferred are quixai or oxaxyl groups.
- an aki group having a prime number of 2 to 4 is preferred, and an aki group having a prime number of 2 to 3 is more preferred.
- R is at least an elementary atom, and when is 0, RR is at least one C and more preferably both C. It is.
- it is a glove, an oxygen atom, a C 3a, a C C2-3 aki, an alk group having or without substitution, and more preferably is there.
- nigga group Is preferably the above, but preferably, or a with 2, or with or without 2, or with or without 2, with substitution or with a prime number of 3 to 8 quakes, or 2 with or without prime 3 to 8 quakes, or 2 with or without prime 3 8 quas, or 2 with or without prime 3 to 8 qu A, nigga group can be mentioned.
- a group can be listed, but 4 groups are preferred. Specific examples of such groups include O 2 and Off 3 groups, but the O 2 group is preferred. Specific examples of such groups include furai and la 3i groups, and la 3i groups are preferred.
- Preferred examples of the zeolite include a group having or not having. As mentioned above, it is more preferably a group having no substitution. Li-group and group-bonding are not limited, but the base sites 2 (Kino 2 I), 3 (Kino 3 I), 6 (Kino 6 I 8 (Kino 8 I, and the base field 4 (Iso 4 A) 5 (iso 5 a).
- a quake having a prime number of 3 to 8 it is preferable to have a qua group having or not having a qua group having a prime number of 3 to 8, and having a prime atom as a child, preferably having a valence group having 5 or less.
- a oxa group having or not having a oxa group can be mentioned.
- Specific examples of kissa are KUXI KUXI 2, KUXI 3, KUKIA 4, and XXER 5
- Ixar 6a group can be mentioned, but a xy group is preferred.
- Examples of the prime of 3 to 8 include a oxa group having or not having 6 atoms having an oxygen atom as a child.
- Examples of the group include a do 2H group, but a 36-do 2H group is preferable. As mentioned above, preferred is a qua group rather than a qua group without substitution.
- adduct having or not having an adduct As an adachi, mention may be preferably made of an adduct having or not having an adduct. As an adachi, the preferred type is a die group.
- a), (TD) R can be arranged at any position of the ot, meta and la positions of the z ring to which the group is bonded.
- TD is a preferred meta or la of the above-mentioned ring, more preferably a position, and R 3 and other positions.
- R is the above-mentioned ZE ring.
- the above-mentioned ZE ring can be placed at any position, but it is preferable to place them at each position.
- biological compound (a) of light bo (zecabo) or boric acid (a) shown below can include the following compounds: 5 2 3 3 3 3 Iano) Benzoic acid ( 2) 2 Bi 3 Iano 5 benzoic acid (4)
- R and R are as described above, but preferably the same or Unlike the above, there may be mentioned an alkyl group having an alkyl group having 6 to 6 carbon atoms, or an alkyl group having 2 carbon atoms.
- Aki is preferably a prime number of 4 and more preferably a methy group.
- a group can be preferably mentioned as a. Although it is a place for the ant group, it is preferably a substitution group.
- R and are preferably one (R located at the 4-position of the o-ring) a and the other (eg R located at the 5-position of the o-ring) is the grave.
- R and are the same as above, but are preferably gale and R and R are both elementary atoms.
- a cu group is preferably exemplified. it can.
- examples of a include dithio and ri groups. It is re-base.
- Specific examples of the ligand include a rai group and a rai group, but a rai group is preferred.
- the qua and ant groups are groups having no substitution.
- (A), (T D) R and R Can be placed at any position in the ZE, MET and LA positions of the ZE ring to which the group is attached.
- (T D) is preferably arranged in the z-ring or in the la position, and is arranged elsewhere. When R is 0, R and R can be arranged at any position of the above-mentioned zeal ring.
- R-R. , XD is as described above.
- “2” may have a substitution to 6 alkyl.
- the compound (a2) is represented as a prime number 6 aki, preferably a prime number 4 aki, and more preferably a prime number ⁇ 3 aki.
- the aki group can be straight or tangent.
- the alkyl group may have or 2 but is preferably a substituted alkyl group.
- Preferred examples of the compound (a 2) include compounds in which (a 2) and X are (C C).
- B and R and R Can be placed anywhere. Further, there can be mentioned compounds in which B is present at the ot position of the above-mentioned ze ring, and at the meta and la positions, respectively.
- R are as described above, but preferably the same or different, a hydrogen atom, or an ant having 2, or 2 or And 5-6 groups having or not having. More preferably, R located in the meta position is a hydrogen atom, and R atoms located in the la position, having or not having, or having 5 to 6 having a group having or not having is there. It is a good child.
- preferred examples of the atoms include an elementary atom, an elementary atom, and an atom, but more preferred is an elementary atom.
- Preferred examples of the ant include a group, and examples of the 5- to 6-a include a group in which the shift of an oxygen atom, a child, or an element atom is the same or different, or 2. It is a 5-6a group with oxygen atoms as children. More specifically, it is possible to list Rai, Rai, La3i, Hula4i, and La5i groups. More preferred is the La 3i group.
- the position of the ant group and the a group is as described above, but it is preferable that the atom is an atom, and the number of carbon atoms is ⁇ 6, and is suitably ⁇ 4).
- R R is as described above.
- R is an atomic atom.
- R is a hydrogen atom, and the other is a prime number 6 with or without substitution, preferably a halo group.
- Preferred examples of the state space include an e-thio group.
- a group it is preferable to use a group as a group, preferably as a group, and more preferably as a fura group and a fura group as a group.
- a kuxa is preferred, a quixai group is more preferred, and a dantai group is preferred.
- (a 2), (TD), R, and can be arranged at the positions of the ZE ring to which R and are bonded, and at any position in the la position.
- (T D) is preferably arranged in the above-mentioned zet ring or la, more preferably in the position R and in other positions. When R is 0, R and can be arranged at any position of the above-mentioned zeal ring.
- biological (a 2) of the acid include the following compounds: 5 (2) (3 (La 3a)) Anobenzoic acid () 5 2 3 (La 3a) Benzoic acid (5) 2 3 e) ano5 benzoic acid (6) 5 ku2 (2 quino) benzoic acid (7) 2 (4 e franco5 benzoic acid (8 ) 2 (Bi 4 Oxano 5 benzoic acid (9) 2 (Bi 3 Oxano 5 benzoic acid (2) 2 4 Adatyano 5 benzoic acid (2)
- Oxanobenzoic acid (6) a 3) may be substituted up to 6, C2 to 6, or C2 to 6
- ⁇ Rr ⁇ R. x, ⁇ D is the above.
- Compound (in a 3, (indicated by) is an alk of prime to 6, carbon of 2 to 6, and aki of 2 to 6.
- the aki group may be in the form of or a different form, and the part of the aki atom is a prime number 3 to 8
- A is preferably a group having a prime number of 2 to 3, and more preferably a group.
- Preferred as the quinone is a quinone having a prime number of 2 to 3, and more preferred is a primal number 2 aki group. These tombs have or 2 You can also. As mentioned above, it is preferable to use the aki, aki, and aki groups.
- Preferred examples of the compound (a3) include compounds in which (a3) and X are (CC).
- B, R and R can be placed at any position in the ZE, MET, and LA positions of the ZE ring to which the group is bonded. More specifically, a compound in which B is at the auto-position of the above-mentioned zet and R and R are at the meta- and la-positions, respectively.
- R and R are as described above, and preferably, they can be the same or different and include a hydrogen atom or a gate. More preferably, R located at the meta position is a hydrogen atom, and R atoms located at the la position.
- R located at the meta position is a hydrogen atom
- R atoms located at the la position are preferred.
- a genus preferred are an atomic atom, an elementary atom and a diatomic, and more preferred is an elementary atom.
- R R Is the above, but preferably when R is R R. Both are elementary atoms. Is preferred.
- a group can be preferably mentioned.
- examples of a include 5 or 6 ants having an oxygen atom or an elementary atom as a child, preferably a Li group and a di group, and more preferably a La 2 group, a La 3 group, and a 3 group.
- Zoari is preferred or Li group, more preferred
- Examples include i, 3 i, and 5 i.
- Preferred examples of quals include kuxa, more preferably kuxai groups.
- a preferred example of the adachi is the daitai group.
- the nigga group The nigga group.
- (A 3), (TD), R and R Can be placed at any position in the ot, meta, and la positions of the ring that is attached.
- TD is preferably located at the position of the ring or above, more preferably at the position, and R and at other positions.
- R and R Is an arbitrary position of the above-mentioned ZE ring can do.
- the following compounds may be mentioned as the bright bo (bozebobo) or its physical properties (a 3) indicated by
- Ano5 benzoic acid (94) a 4) may be substituted up to 6 Aqui CO, CO, may be substituted up to 6 CO or a compound that is a curtain represented by the formula
- CH. May have a substitution on a carbon atom, or a part may form a cycloalkyl group.
- compound a 4 is represented by C to 6 aki CO C C to 6 aki CO, or a group represented by the formula:
- 1 to 6 aki 6 aki The aki represented by CO is aki having 6 to 6 carbon atoms, preferably priming to 4 and more preferably priming to 2 aki.
- the aki group may be in the form of or, and the aki atom may form a quaternary ring of 3 to 8 primaries. Examples of quakis include kuup, kubutan, kuputa, kuqa, kuputa, and kuocta, but kupu is preferred.
- Machi is an Aki group.
- 1 6 aki to 6 aki C may have one or 2 in the aki group. As described above, a substituted alk group is preferred.
- In (), is O or. Is an O ⁇ 2 number, but is preferably 0 or.
- C) an elementary atom may have or of 2. Examples thereof include a genus, an aki having 6 to 6 carbon atoms, an aki having 6 to 6 carbon atoms, and an aki having 3 to 8 carbon atoms. (C. is preferably an alkyl group having no substitution.
- Preferred examples of the compound (a4) include compounds in which a) and X are (C C). , B, and can be placed at any position of the ZE, MET, and LA positions of the ZE ring to which the group is bonded. More specifically, examples include compounds in which B is in the above-described ZE ring ring and R and R are in the meta and la positions, respectively.
- Compound (in a 4, and R are the same as those described above, but preferably, they may be the same or different and may be a hydrogen atom or a hydrogen atom. More preferably, in the meta position. R located is a hydrogen atom, and is located in the La position is a getom, where as a gantry, a prime atom, a prime atom and an atom are preferred, and a prime atom is more preferred.
- RR is as above, but is preferably RR. But, Or, alternatively, a hydrogen atom or a prime number to 6-alkyl group. Examples of RRs are preferably prime numbers of 4 to 4 and more preferably prime numbers of 2 to 2. Preferred as RR is that both are hydrogen atoms, one is a hydrogen atom and the other is an alk group. Can be mentioned.
- a genus an atom group having a carbon number of ⁇ 6, suitably ⁇ 4 aki, and a prime number of ⁇ 6 (suitably ⁇ 4).
- an ant it is a group having a genus and a gate as an ant.
- a genus it is preferably an atomic atom and an atomic atom, and more preferably a fluorine atom.
- ants preferred are Li, and more preferred are La 2 and La 3 groups.
- a nigga it is preferable to mention a navy group.
- the position of the ant and nigga groups is as described above, but the preferred ant and nigga groups are preferred.
- (TD) R can be placed at any position in the, meta, and la positions of the ZE ring to which is bound.
- (TD) is preferably the above ZE ring or R is more preferably arranged at the position, and R and are arranged at other positions, but R and can be arranged at any position of the above-mentioned ZE ring.
- R-R. , XD is as described above.
- Preferred examples of the compound (a5) include compounds in which (a5) and X are (C C).
- B, R, and Z can be placed at any position on the het ring where the group is bonded. More specifically, there can be mentioned compounds in which the o-position of the above z-ring is R and R in the meta and la positions, respectively.
- R and R are as defined above, and preferably, they can be the same or different and include a hydrogen atom or a gate. More preferably, R located at the meta position is a hydrogen atom, and R located at the la position is a genus.
- R located at the meta position is a hydrogen atom
- R located at the la position is a genus.
- a genus preferred are an elementary atom, an elementary atom and a fluorine atom, and more preferred is an elementary atom.
- R R are as described above, but preferably is 0, one of R R is a hydrogen atom, and the other is an alkyl group having a prime number of 6. Preferred examples of the space include prime number-4 and more preferably prime number-2.
- (a5), TD), R and R can be placed at any position of the ot, meta and la positions of the ze ring to which the adduct group is bonded.
- (TD) is the preferred position of the above Zen ring or La, and more preferably , R and R. Are placed in other places.
- R and can be placed at any position in the above Zen ring, but it is preferable that one of them be placed at the La position.
- the compounds belonging to (1) include those represented by the following formulas (b) to (b) or complex and physical properties.
- R and R are as described above, but are preferably the same or
- a hydrogen atom or a genome can be mentioned. More preferably, is located at the meta position is a hydrogen atom, and is located at the la position is a gem.
- a gene an atom is preferable, an atom and an atom, and an atom is more preferable.
- R is as described above.
- R is a hydrogen atom
- R is a gate.
- a genus preferably an atomic atom and a bromine atom, more preferably an atomic atom.
- R is a hydrogen atom, an aki having 6 to 6 carbon atoms, or an aki group having a prime number to 6;
- Achi is preferably a prime group having a prime number of 4 and more preferably 2, or a deviation of the shape.
- the Akiaki group is preferably a prime number ⁇ 4, more preferably a prime number ⁇ 3 Aki group, or may be in a different form.
- the Akiaki group is preferably a prime number of ⁇ 4, more preferably a prime number of 3 Aki groups, or it may be misaligned.
- Preferable is the gong board.
- A is as described above, but is preferably an ali group having or not having 2, and an ali group having or not having 2.
- the group A is as described above, and preferably includes a group having or not having a group. This is as described above.
- M is a substitution group.
- the above group A is as described above, and preferably, a lan 2 group and a fura 3 group can be mentioned.
- the compound (b) is the above-mentioned, but is preferably a bond, or has a bis of 2 or an aki of a prime number to 6, or
- the alkyne group is preferably a prime group of ⁇ 4, more preferably a prime number of 3, or may be misaligned. Preference is given to compounds (b), compounds of compound (b), compounds (b), or an alkyl group having a prime number of 6 having or not having 2.
- (b), (E) and R can be placed at any position of the id group, but (E) is preferably placed at the 5-position, and R is preferably placed at other positions. Better .
- R..x Y and A are the above-mentioned compounds (c) include compounds in which (c) X is (CC). , B, R and can be placed at any position on the ZE, MET, and LA positions of the ZE ring to which the group is bonded. Further, there can be mentioned compounds in which B is in the above-mentioned Nze ring oto position and R and R are in the meta and la positions, respectively.
- R 1 and R 2 are the same as those described above, and preferably, a hydrogen atom or a hydrogen atom can be exemplified as the same or different. More preferably, R located at the meta position is a hydrogen atom, and R atoms located at the la position.
- R located at the meta position is a hydrogen atom
- R atoms located at the la position are preferably an atomic atom, an atomic atom and an atomic atom, and more preferably an atomic atom.
- Y is the above, a child or an oxygen atom.
- A is as defined above, but is preferably a group having or not having 2. More preferred are groups with or without Can. Here, as mentioned above, the preferred is a monster. As a molecule, preferred are an elementary atom, an elementary atom and an atom, and more preferred is an atom.
- the compound () is the above-mentioned, but is preferably a gong board.
- R R,, x ⁇ "G is preferably the compound (d) mentioned above, wherein (d) and X are (C C).
- B, and R can be placed at any position of the zen ring oto, meta, and la positions to which the group is bonded. More specifically, examples include compounds in which B is in the above-described ZE ring ring and R and R are in the meta and la positions, respectively.
- R In the compound (d), and R are as described above, and preferably, they can be the same or different and include a hydrogen atom or a gate. More preferably, R located at the meta position is a hydrogen atom and is located at the la position is a gem.
- the Gunn preferably an atom, an atom and an atom, and more preferably an atom.
- the compound (d) is as described above, but preferably is a gaddo, or an aki of a prime number of 6 having or not having 2 (the prime atom part of Or may have a ring), or may have 2 or may have a prime number of 6 to 6 atoms may form a quack ring), or have 2 or
- the prime atom number of 6 to 6 and the aki group may have a quasi-ring. , 1 4, or There are 4 aki groups with prime numbers ⁇ 6.
- examples of aki, aki, aki and aki 4 include aki groups having from 6 to 6 carbon atoms, preferably from prime numbers to 4, more preferably from prime numbers to 2. It is a key group.
- the aki group may be in the form of a stagnation, or the aki group may form a quasi ring having a prime number of 3-6.
- Examples of kuaki include cup, kuta, kuputa, and kuxi, but kuup is preferred. These groups can also have or 2 but are preferably substituted aky groups.
- G is a hydrogen atom or a prime 6 alkyl group.
- Preferred as an aki is a prime number ⁇ 4, more preferred is a prime number ⁇ 2.
- Zingbo or its physical properties (d) are as follows:
- R 1, R 2, R 3, R 4, and x 5 are preferably the above-mentioned compounds e), e.g., compounds in which e) and X are CC).
- B, R and can be placed at any position of the zeo ring oto, meta and la positions to which the group is bonded. More specifically, examples include compounds in which B is in the ot position of the above ring and R and R are in the meta and la positions, respectively.
- R and are the same as those described above, and preferably, the same or different, a hydrogen atom or a gate can be mentioned. More preferably, is located at the meta position is a hydrogen atom, and R located at the la position is a genome.
- a genus preferably an atom, an atom and an atom, and more preferably an atom.
- compound e is as described above, but is preferably a box, or a group having 2 to 6 primes having or not having 2.
- a is preferably a group of prime numbers 2-3, more preferably a group of prime numbers 2.
- the group A may have 2 or 2, and examples of the group are preferably a genus.
- a genus it is preferably an atomic atom and an atomic atom, and more preferably an atomic atom.
- Compound (In e, R and are the tombs that are both hydrogen atoms or aki groups and are bonded together to form 3 to 8 quacans. It is preferably 3 6 quaca, and more preferably 6 ring oxa.
- (e) means a single bond or a double bond.
- the o group bonded to the group is not particularly limited, and can be bonded to any position, but preferably a compound represented by the formula in which the fo group is bonded. be able to.
- R,,, x ⁇ are the above compounds), preferably (), X is CC)
- the compound which is can be mentioned.
- B, R and can be placed at any position of the ZERO ring, meta and la positions to which the group is bonded. More specifically, examples include compounds in which B is in the otto position of the above-mentioned ZE ring and R and R are in the meta and la positions, respectively.
- R 1 and R 2 are the same as those described above, and preferably, they are the same or different and include a hydrogen atom or a gate. More preferred is an R hydrogen atom located at the meta position and an R hydrogen atom located at the la position.
- R hydrogen atom located at the meta position
- R hydrogen atom located at the la position.
- a genus preferably an atom, an atom and an atom, and more preferably an atom.
- the position of the group bonded to is not particularly limited, and can be bonded arbitrarily, but preferably includes a compound represented by the formula in which four groups are bonded. it can.
- Rr R, x are as defined above.
- R 1 represents a compound (9 is preferably 9), and X is (C C).
- B, R and R can be placed at any position of the ring oto, meta and la positions to which the group is bonded. More specifically, there can be mentioned compounds in which the above-mentioned ze ring is at the ot position and R and R are at the meta and la positions, respectively.
- R and are the same as those mentioned above, but preferably, they can be the same or the same as a hydrogen atom or a genome. More preferably, R is located in meta. Is a hydrogen atom, and R in the La position is a gene, where as a genus, an element is preferably an atom, an atom and an atom, and an element is preferably an atom.
- the compound () is as described above, but preferably is a good.
- the group may have a substitution (g).
- Gunn, C4, C4, C4, C4, C4, C4, C4, C4, C4, C4, C4, C4, C4, C4, C4, C4 Examples thereof include an acryl group having an alk group having 4 carbon atoms, such as a galley, an ano, a force, and an alkyl group.
- Aki, Aki, and Ali are as described above. It is preferably a group having or not having 2, and more preferably a group having or not having.
- the position of the group is as described above, but a substituent is preferred.
- the compound () targeted by Ming may be either in the form of a salt or in the form of a salt.
- organic compound examples include those that are usually pharmaceutically acceptable, such as or organic groups, or basic anions and salts.
- organic groups such as or organic groups, or basic anions and salts.
- Acaum such as Toumumumum, etc.
- Aum Aum etc. can be mentioned.
- Tanoa, Tomethan, Thithia, etc. First-class Achia, Tanoa, N, Ku, Chijia, etc., Second-America, Tothia, Piji
- Examples include Tanoa and the like.
- Examples of basic anions include egi, di, uchi and hiss.
- Inorganic acids that may form organic acid salts include hydrochloric acid, hydrofluoric acid, and acids, and organic acids include tofu, in, tartaric acid,, lactic acid, meta You can show Suho, Zesuho, Tosuho.
- boric acid biological compound and its salt form a solvent (for example, a)
- a solvent for example, a
- all of these are clearly included.
- a ste () of a bright or complex boric acid can be produced s ep (a).
- Ste () prepared by water decomposition or contact by the kind of R,
- the compound (2) corresponding to a clear or complex boric acid can be produced by selectively removing s e b)
- R 1, x, ′, and A are the same as above.
- R represents a prime alkyl allyl or aralkyl group.
- the compound () can be reacted by reacting the compound (2) with its own mixture, or by introducing the compound (2) to a reactive conductor and then reacting the compound ().
- CC water-soluble
- SC water-soluble
- 33 Methylopopidoacid salt such as 33 Methylopopidoacid salt
- zo C
- zotriazo oxinos dinoxoxato POP examples of the method for producing stete include N-kik (OS) zotoazo OB).
- compounds such as 2 conductors such as kud (ku, pu, etc.), active stadium (P tofu ste, peta ste, N ki ster, zozo azoste, etc.), mixed water ( Toki, Toki, Popoki , Toki, Isotoki, eToki, Fuki, 22 Mepio Pio, Metashon, Nzesuho, Tosuho, etc.).
- 4-methylamino) or N-methizo may be added for further activation.
- These responsive conductors may be compound () reacted while being produced or produced in the reaction system, or they may be separated from the reaction system to react with the compound ().
- the compound () and (2) the compliant conductor are usually performed at the base if necessary. In general, it is generally used, but in some cases, water can be dissolved, and some of these compounds can also be used. For example, geaki (methi, quam, etc.), hydride, to, ki, azo, etc.), te (tesopitite, metite, mechpetite, tetrad La (), Kissa, etc.), Stes (Meth, Chi, Soppi, Chi etc.), Tos (Tomethyto, Mechito etc.), Acetori, NN Examples thereof include inorganic compounds (sodium oxyhydrogen, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, water.
- the combined dose and base dose are usually ⁇ 5, preferably ⁇ 3, relative to compound (2). When compound 2) is used in reactive conductor form, the dosage is ⁇ 5, preferably ⁇ 2, relative to compound ().
- Ste () prepared in this way can be prepared into a clear compound (2) having the form of released boronic acid by cleaving the bond.
- an acid such as a hydrogen chloride field, hydrogen chloride, metasho, zesho, ptosho, and tonic acid is preferably used.
- the reaction can be carried out in a normal solvent (eg, ze, to, chite, isopite,, chi, meta, chem, etc.) at about ⁇ Ox.
- the amount of acid used varies depending on the type of acid, but is generally 0 to 0).
- triacid when triacid is used as this, it may be used as.
- R In the case of a normal aki, ant, or arachi group, hydrolysis reaction with squid can be used.
- the kari to be used is titanium hydroxide, As sodium, potassium hydroxide, hydroxide, etc., methano, tano, oxa, or a compound thereof can be used.
- Aca dose is usually 3 compounds
- Aka Water splitting produces the first salt of Akari, so it can be isolated as it is, or it can be isolated as a separate water by neutralization with (,, hydrochloric acid,) .
- it can be converted to Akari and Akari by the method itself.
- the compound (1) when the compound (1) has basicity in the molecule, it can be released as (1) by treating with an excess amount of acid.
- the compound () can be led to the free boron (2) by using hydrogen gas such as radium and radium black by the method itself.
- Manufacture 1 as shown in the formula.
- the compound in p instead of having a ge group (compound (3) can be produced by reacting with (2) can be produced as sep a)).
- sec (2) can be produced by converting Ha (or) to a base (2) corresponding to a bright or heteroboric acid.
- non-gas atmosphere such as nitrogen gas, a gas, tetradola, dite, dippite, chimete, oxa, etc. Is between 8 and 2 degrees, or preferably an organometallic (eg n-thium, sec-thium, lithium or also.
- the dose of the group is usually ⁇ 5, preferably 2 3 for compound (3).
- the tri-compound (4) can be easily prepared by reacting the compound (2) using () instead.
- the compound (3) having a tetrazol-5a group can be produced by reacting the compound (4) thus obtained with azide 5) as shown in the following formula. sed
- R, x, A, and ⁇ are the same compounds (4) Aji (5) Azinatome, Trimethy, etc.), and usually, khom, to, Ki, dite, , Acetate, c S, Tano,, or these), preferably in a chair (such as Chickle, Thioki) or a chair (Zinc, Copper, etc.). , Normal .
- the azide compound dose is usually ⁇ 0, preferably ⁇ 5, relative to compound (4).
- the compound dose is usually 0.5 for compound 4), preferably 0-5.
- the amount of isosic acid used is usually from 5 to 5 and preferably from 0 to 5 based on the compound (4).
- the reaction may be insoluble in the reaction, for example, hydrogen fluoride (e.g., xanthan, puta, kuxa, etc.), ge hydrocarbon (e.g., meta, quame, etc.), hydrogen fluoride (E.g., ze, to, ki, aso, etc.), Te, e.g., chite, isopipe, etc.), stee (e.g., meth, echi, e.g., etc.), xy, te, etc. , Acetate, Business, c, etc.
- the compound (6 doses is Compound 2) is ⁇ 2, preferably ⁇ 1.5.
- the groups that can be obtained are up to 3, and preferably up to 2, sodium oxyhydrogen, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, water, and 2 to compound 2).
- Bases such as titanium, hydride, tetramethyl, trimethyl, N-methidine, N-methyl and the like can also be used.
- step 3 To (4) prepared in step 3 is prepared by reacting with hydrochloric acid 7) to produce adoxy 8) and then reacting with active compound (9).
- a compound (4) having a group can be produced se
- the dose of (7) and base is usually ⁇ 2 and preferably ⁇ 1.5 for g 4).
- 4, 5 Do 5 4H 2 4 Compound having an azo 3 group (4).
- (8) includes the solvent quant, to, ki, te,, xy, meth, acetri,
- the compound (5) having a 45 4 5 4 2 4 azo group can be produced by reacting the compound (8) prepared in 5 with a carbozo (C)), preferably with a group.
- C carbozo
- R, R, A ⁇ ”, and x are the same as above.
- examples of such materials include quam, to, ki, te,, kisa, chi, aceto, methito, acetate, cSO, tano, and the like.
- Thia, methyl, pyridi, BB, sodium hydride, etc. can be used as the group.
- C ⁇ the preferred range is 0 ⁇ 50.
- C and base doses are usually ⁇ 0 for compound (8), preferably ⁇ 5.
- R, RA, and x are the same as above. It is usually 30 ⁇ , preferably O ⁇ 5O.
- the dose of C is usually ⁇ 3 for compound (8), preferably ⁇ 1 ⁇ 5, and the dose of trifactose is usually ⁇ 0, preferably 3 ⁇ 6 for compound 8)
- the dose of lizard is usually ⁇ 5, preferably 5 ⁇ 20, relative to the amount of compound (). Usually, it is 30 ⁇ , and the preferred range is O ⁇ 50.
- Compound (3) can be produced by combining s e), and step () or ano (5) can be prepared by coupling with a) or) s ep
- the compound () or 5) thus prepared can be made into a clear or complex and its physical (1) in the same manner as shown in Production, 3, 4, 5, or Production 6.
- R R, D, “, and x are the same as above.
- A represents when W of the group represented by the following formula XV is a group substituted with D Ta D Tb, or W of the group represented by the following formula XV or X is a group substituted with D Ta.
- a represents a steal CR), or an ano group.
- A is a logene as W, or is represented by the following formula XV or XV having a trifluoromethanesoxy group.Ta represents a single bond or a prime alkyl, and T represents a triple-bonded alkyl.)
- R Rr A hydrogen atom or an alkyl group is shown, and in the case of an alkyl group, an R group may be bonded to form a ring.
- Z V Z is a child, V is a rogen. Indicates.
- W represents a rogen or trifluoromethane oxy group In (In production, (a Compound (3) can be produced by applying similar conditions.
- Compound (3) is used in the reaction to produce a clear or heteroborate ester () or compound (5)),
- R) RR 4 represents a hydrogen atom or an alkyl group, In this case, R and 4 players may combine to form a ring. ), Or Z V Z is a child V is a gate. ).
- the compound (3) and the compound represented by) are reacted as necessary.
- W class, class, class, etc. when using a compound that is (R.R, ie, or () ste, for example, radium (tetrakis trififty) radium 0, bis (lead ) Radium 0, radium, etc. are preferred, and as indicated by W, elementary atoms, elementary atoms, atoms, and thiometasoxy groups are preferred, and elementary atoms, triometasoxy groups are particularly preferred. .
- reaction 20 is preferably 30 V to 100).
- 5 for compound (4) preferably 1 ⁇ 5 to 2
- the dose is 0 ⁇ 05 to 0.5 ⁇ 5 for compound (4), preferably 0 ⁇ 1 0 ⁇ 2.
- Z indicates a child, and indicates a child.
- radium (tetrakisto) radium 0), bisdide) radium 0, radium) it is preferable to use radium (tetrakisto) radium 0), bisdide) radium 0, radium), and the dose of () is ⁇ 3 for compound 3, preferably 5 ⁇ 2.
- the compound represented by (5) can be converted into a compound (3).
- a catalyst such as Gand, copper, etc. composed of a phosphide compound such as a radium compound is given.
- the above radium forms include, for example, bis (tossi) radium, bis (tosphine) radium, tetrakis (tosfin) radium, etc.
- copper is an example of the above-mentioned compound
- examples of the compound that is the above-mentioned ligand include trie, toss (2 methif), tris (3 meth).
- S Toss (4 points) In, toy, total in, special, tori, triqui, to.
- the amount is not specifically defined, but specifically, for example, bis (Toy) radium
- tin compound (5) 0 to 0 to 5 ⁇ 5 O is preferred for the tin compound (5). It is 1 to 20 for bis (toy) radium cricket. In addition, it is ⁇ 0 for copper bis (t) radium.
- the dose of compound (5) in response is generally from compound (3) to 10. For example, a system such as chia, tritia, and chia is used. If these materials are difficult to dissolve,
- the dose of the system in the reaction is not particularly specified, but it is generally 2 to the amount of raw material. Depending on the type of reaction used in the reaction, it is room temperature to 9. However, the reaction time is not particularly limited.
- Ste (), ge 4) or ano (5) for producing a compound represented by the following formula (wherein the atom part may form a quackyl ring) can be prepared by the following method.
- Compound (7) is reacted with (Compound Compound) or () to produce Compound (7), and then reacted with Compound (8) to obtain a Stein (), Ge (4) or Ano ( 5 can be prepared 7
- R 1, R 2, x,, and A are the same as above.
- b represents a ste (CoR), a rogenoio or an ano group.
- R indicates elimination.
- • a may have a substituent, and a part of an elementary atom of an alkylene alkylene having a number of to may be a cycloalkyl ring. Examples of R used here include ge (, chlorine,), or oki (, meoki, oki, oki), and the like.
- s ep can be performed by applying the same conditions as s e a in manufacturing.
- the compound of s e) (7) can be prepared with a general group of,, about Ox, preferably about ⁇ .
- Examples of groups include sodium hydride, potassium hydride, potassium carbonate, sodium carbonate, sodium hydride, and so on.
- hydrogen fluoride for example, xya, penta, kuxa, etc.
- ge hydrocarbon for example, meta, kuta, quam, etc.
- hydrogen fluoride E.g., ze,, ki, aso, etc.
- Te e.g., chite, iso-pipete, etc.
- tons e.g., to, metito, metito, etc.
- xy, aceto, pig, c etc. or these are used.
- R R, x,, b and A are the same as above.
- P is an ano group.
- the protecting group of an ano group include okikabo and tokikabo. s ep, se P, as well as Sep a in production
- (4) or (5) can be prepared by the following method to produce a compound represented by the following formula: , 3, 4, 5 or 6 in the same way as shown in or complex and its physics 1).
- R, R ⁇ F, x ⁇ "a, b P and A are the same as above.
- s ep s e S) can be performed by applying the same conditions as s e a in manufacturing. This can be done by applying s ep (similar conditions of s e to manufacturing 0).
- Compound (), Compound () or Compound) can be easily prepared by reacting. It is usually used for sex. Examples of organics include guachi (meth, quam, etc.), hydrogen fluoride, te, quin, asso, etc., and te (so, soap, meth).
- organic materials include Geachi, Mekki, Kuhom, etc.), Hydrogen hydride (Ze, To, Ki, Aso, etc.), Te (Te, Sopite, Mechite, Mechichite, Kisame, Kisame, etc.) Etc., Ste, Met, Soppi, H, etc.), G (Ton, Met, Metito, etc.), Acetate, c N Method, Method, etc.
- These groups include inorganic (sodium oxyhydrogen, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, titanium hydroxide, etc.), (zinc, titanium, NN soft Pichia, N-methyl, N-methidine, etc.).
- R 1, R 2, x, and A are the same as described above. Usually, about 5 OV to O, preferably 30 T to 8 can be performed.
- hydrogen xa, puta, kuxa, etc.
- hydrogenated hydrocarbon metala, khom, etc.
- hydrogen hydride ze, to, ki, etc.
- Aso, etc. Te (Te, Isopite, etc.)
- Ste Metal, Chi, Chi etc.
- Kissa Ace, Virig, c, etc.
- Isoanato compound 28 Dose is ⁇ 2 for compound (), preferably • 5.
- step (1), step 4) or ano (5) are As shown in the formula, the compound () or () Kuto 29) is allowed to act to synthesize the methoxy intermediate, and then the same compound 3 or compound (3) is allowed to act (v).
- the compound () 4) or (5) prepared as described above can be prepared in the same manner as shown in Production, 2, 3, 4, 5, or Production 6 or as complex and its physics) .
- R R R b, A, and x are the same as above.
- compound () or () Kutofu 29), with appropriate pyridine, pi, 4 methanoid, tothia, methid, methly, etc.) Approx. 2 to Ox, preferably 3
- the compound represented by (2) in which is represented by aki, is obtained by reacting compound (32) ano compound 3) with The compound corresponding to the acid (2) can be produced se)
- Rr R, x, “a R and A are the same as defined above.
- C ⁇ Preferably, it can be done at every point.
- the group include sodium hydride, potassium hydride, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, and so on, and so on.
- hydrogen fluoride eg, oxa, puta, coxa, etc.
- ge hydrocarbon e.g., ge hydrocarbon, etc.
- the compound (34) can be produced by reacting the compound 33 shown in the following formula instead of the compound 33 shown in the formula 1 instead of the compound 33 in the formula 1 s x).
- the compound 5) can be produced.
- the compound (), or (5) prepared as described above can be made in the same manner as shown in Preparation 2, 3, 4, 5, or 6, or complex and physical (1) .
- compound (33) was used instead of 8 sek compound (3).
- By carrying out the reaction it is possible to produce the raw materials)) used in the above ⁇ 5 and 7 ⁇ 6.
- Rr represents an alkyl, aryl aralkyl, or hydrogen atom.
- A is the same as in (2 8), but the compound (35) is reacted with compound (4) or (5) in the same manner as in production 8 (sep k) to give compound (36).
- the compound (36) prepared as seaa) can be prepared next, and the compound (2) can be easily prepared by reacting in the same manner as in production seb).
- R is a hydrogen atom
- compound 36) is the same as compound (2), and compound (2) can be prepared only with seaa.
- the compound 2) thus prepared can be prepared in the same manner as described in the production, 2, 3, 4, 5 or 6 or as a complex and its physical (1).
- the intercalation compound 3) can also be produced by the following method.
- step (7) prepared in step 9 of production 9 ste or ano (37) may react with compound 38) instead of se compound (8) to produce compound 3).
- ste or ano (37) may react with compound 38) instead of se compound (8) to produce compound 3).
- R 5 is an alkyl reel, or aralkyl is optionally substituted with a prime number of
- compound (40) can be easily prepared by reacting compound 38) and 39) et al.
- S ep (b) The compound (4) can be easily prepared by reacting under the same conditions as above. S ep, and further manufactured. By reacting under the same conditions, the compound 3) can be easily prepared.
- the path is provided as P in (1) above. That is, P containing the compound () described above as an active ingredient is provided. In other words, it has the above-mentioned compound 1 having clear P and P harmful activity as an active ingredient.
- the P-poisoning activity of the compound () can be evaluated using the Ibi assay system.
- An example of the Ibi assay system is the method of measuring the P movement of (1) with respect to the tissue plasmonactivator (P). In addition, it can be determined by using the reaction caused by P for P and R as an index.
- an ibi assay system for measuring P activity using as an index the amount of P produced by the use of P for color development 2288) is exemplified.
- P 1 harmful activity can also be evaluated by measuring the behavior of () in combination with P P (PP combination) by, for example, the west-batching method.
- P P the higher the P 1 harmful activity.
- the compound (1) can prevent or ameliorate tissues and tissues (such as symptoms and the like) based on the action of inhibiting the P property.
- P various types reported to be related to P (species, cancer, urinary and urinary complications, glaucoma disease, multi-modality, radiation damage, alopecia), obesity and vascular sclerosis It is useful for the good of symptom) (2 7).
- a compound having a clear P 1 and P 1 harmful activity 1) is used as an active ingredient.
- P 1, 1) 00 may be used as long as it contains an effective compound (1) that exhibits PA 1 harmful activity.
- P 1 usually contains the compound () in the range of 0 to 99, preferably 1 to 80.
- a pharmaceutical comprising the aforementioned P as an active ingredient. Instead, it clearly has the compound (1) described above as an active ingredient.
- the effect for P 1 is demonstrated, and as a result, the positive and negative solutions are increased by the plus, and the action of promoting the living body is improved or the deterioration of the living body is improved. Has the effect of For this reason, it can be clarified.
- it is useful as a state of or caused by the thrombosis, or under, of the clear, P sex involved in the onset. Or as pathologies, for example, arterial thrombus, venous thrombus, surgical vein (D T), seed tube (DC), urinary complications
- the thrombus in the arteries includes thrombus in the brain (thrombus, brain, transient), thrombosis in the heart, myocardium), thrombus in the lower limb (), and (
- thrombus in the vein examples include a thrombus (partial vein) that occurs in the extremities and a thrombus () that occurs by jumping into the lungs.
- (1) is effective so that it can be used for P, and as a result, has the effect of preventing or improving the organization officer. For this reason, it is useful as an or related to or related to governmental issues arising in connection with sex.
- pathological conditions include, for example, myocardial tissue, and companion tissue.
- PA 1 by demonstrating (), it is effective for PA 1, and as a result, it is useful as an eye as described above. Therefore, it is useful as a prognosis or as a prognosis for Atsui disease.
- the body weight () of the drug is usually 0:00 to 5, especially be able to.
- Illustrative methods can include oral administration, as well as oral, intramuscular, subdermal, oral, oral, and oral administration. More preferred is oral administration and administration, and more preferred is oral administration. Clearly, it can be prepared according to the method. The following explanation is given in parentheses. However, various types that are usually used in the pharmaceutical field can be used, although these are not limited to these.
- oral administration examples include powders, capsules, pills, drugs, tablets, suspensions, emulsions, and poultices, and can be selected from these.
- these preparations can be stabilized, difficult, and enteric.
- an intravenous administration an intramuscular administration, or a subcutaneous administration, there are injection and (including manufactured products), which can be selected.
- laxatives laxatives, laxatives, caps, tochis,, and so on, which can be selected according to the application site.
- these preparations can also be stabilized, difficult and difficult to apply.
- pharmaceutically acceptable can be formulated.
- Scientifically acceptable examples thereof include agents,, TIG, base, binder, lubrication, disintegration, suspension, viscosity, emulsifier, stability, agent, painless, preservation, masking, coloring.
- agent examples include purified water, water for injection, physiology, peanut, tano, and jelly.
- Dep Yodep, Mudeptou Dep
- Doe Sucrose
- Crystalline Sesium Um, Carbonic Carbonate, Sodium Bicarbonate, Sodium Chloride, Tak, Titanium Oxide, Toss Quito etc. can be mentioned.
- Dep and its conductors for example, methesses, ses, hippies, methysess
- gelatin for example, agin sodium, tragato, arabic, etc.
- examples thereof include natural polymer compounds, de- and a-molecular compounds, chists, and hippi-pistachis.
- Kay Stair and its (for example, stearium), Tak, Waxes, Mude, Cu, Hydrogen, Post, Litig.
- Examples include methysses and low pieces.
- Examples include quist, tano, puppig and ligching.
- Examples of the agent include methices sodium, do, arabic, tragato, aginatoum, stearium, cucumber, and the like.
- Examples thereof include methices sodium, de, methises, hippimethyces, a, tragato, arabic, agin sodium, and the like.
- the agent is Arabic, Ste, Tragath, Methesis, Chi,
- kito eg, ogg
- gas eg, carbon dioxide
- substances such as sodium hydrogen sulfate, thionatric, asbi, and lit.
- Examples thereof include sodium hydrogen, sodium, quaternary, and boron.
- Examples of the agent include sodium chloride and grape. This can include local (pucaine, chi), pezia, dough, gull, and ano.
- sugar examples include sucrose, saccharin, oysters, ginger, chito, and liseri Can be listed as Tokyo.
- water-soluble food dyes examples include key.
- Examples thereof include benzoic acid and the like, Laoki benzoic acid stea, kutano, reverse soap, dia, rhino, sa, dehydr, hou, and the like.
- tags examples include sucrose, hydropic PC, shellac gelatin, glycerin, g, hypipimethyces (PC, chiseth, do (P), hypipimethystat (Polmers such as PCP), cetacetate phthalate (CP), and methyl acetate acrylic polymer include seri, fluid lye, now, beef tallow, hardened oil, lye Plant The underwater agent can be mentioned.
- the drag stem (S) technique can be used as described above.
- the S agent is an agent, topical torch, medicine, controlled drug release formulation, intestine and administration route, irability, side effects, and the optimal formulation.
- the oral administration is preferably 3 to 3 O, more preferably 5 O, based on the amount of compound (1). is there.
- administration such that the intermediate concentration of compound (1) is 0 ⁇ 25, more preferably • 5 to 20 can be mentioned.
- the oral administration is preferably in the range of 0-3 to 3 O, more preferably 0. ⁇ 5O weight.
- administration in which the intermediate concentration of compound (1) is 0 ⁇ 2 to 5 and more preferably 0 ⁇ 5 to 2 can be mentioned. These may vary depending on age, gender, and body type.
- Triazo was added to the NN with a zero N N methiade DVIIc), 2.
- HNDS 6 82 2 0 2H) 2 50 2H 7 3 Hz) 3 37 (2H d 6 ⁇ 6 60 Hz 697 7 02 H 7 46 H 7 7 Hz 7 62 H dd 9 ⁇ 0 2 ⁇ 6Hz) 7 68 7 8 3H 7 90 H d 2 6 Hz) 8 04 HS) 8 22 HS) 8 49 H d 90 Hz 8 55 H 60 Hz 04 HS)
- Oxygen of benzoic acid, N, N methihomad (DF), 0 ⁇ 78 3 ⁇ 7 was 30 with 0 THF and 0V. The pressure was reduced. 0 ⁇ 49 9 2 ⁇ 7) 2 ANO 5 chloromethyl benzoate and 5 D c were added to make 0.5. After that, sodium oxyhydrogen solution was added, and the resulting body was treated with PE and 5/6 of 0 ⁇ 639 (3 (Fura 3 Iano) breath) Got Mechi (67)
- a solution of 0 ⁇ 6 ( ⁇ 7) 5 3 3 (La 3 b) aminobenzoic acid was dissolved in 20 T, and 4 N sodium oxide was added, and the mixture was adjusted to 50 with 50.
- the reaction was acidified by adding an acid N, and then the pressure was reduced. I added water and my body was water.
- Compound 4 was synthesized according to the following two items: ep) to (and) to v.
- a compound () was synthesized according to ep to () described below.
- L-Piano benzoic acid was obtained from L-Piano benzoic acid methyl ester 86)
- the compound was synthesized according to ep to) described below.
- the ice of 150 mg (0 761 of 5 rai 1 methy Hid of THF 5 193 52) was adjusted to 4 at room temperature. After depressurizing the excess of THF, add ice and remaining DNo.
- H NM (D) 6 4 gH S) 3 96 3H S) 4 65 2H S 6 85 H ddd J 8020 gHz) 7 08 H ddd J 8 ⁇ 0 2 ⁇ 1, 0 g Hz) 7 20 HJ 2 Hz) 7 28 HJ 8 z) 7 52 H dd J g
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10758123A EP2415755A4 (en) | 2009-03-31 | 2010-03-31 | INHIBITOR AGENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1 |
US13/262,259 US8785473B2 (en) | 2009-03-31 | 2010-03-31 | Plasminogen activator inhibitor-1 inhibitor |
JP2011506826A JP5730190B2 (ja) | 2009-03-31 | 2010-03-31 | プラスミノーゲンアクチベーターインヒビター−1阻害剤 |
CN201080015064.9A CN102378753B (zh) | 2009-03-31 | 2010-03-31 | 纤溶酶原激活物抑制因子-1抑制剂 |
AU2010231058A AU2010231058A1 (en) | 2009-03-31 | 2010-03-31 | Plasminogen activator inhibitor-1 inhibitor |
KR1020117025656A KR101762574B1 (ko) | 2009-03-31 | 2010-03-31 | 플라즈미노겐 액티베이터 인히비터-1 저해제 |
BRPI1013392A BRPI1013392A2 (pt) | 2009-03-31 | 2010-03-31 | inibidor do inibidor-1 do ativador do plasminogênio |
EP13001154.7A EP2607348B8 (en) | 2009-03-31 | 2010-03-31 | Plasminogen Activator Inhibitor-1 Inhibitor |
CA2757615A CA2757615C (en) | 2009-03-31 | 2010-03-31 | Plasminogen activator inhibitor-1 inhibitor |
US14/307,149 US20140296256A1 (en) | 2009-03-31 | 2014-06-17 | Plasminogen activator inhibitor-1 inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-088400 | 2009-03-31 | ||
JP2009088400 | 2009-03-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/262,259 A-371-Of-International US8785473B2 (en) | 2009-03-31 | 2010-03-31 | Plasminogen activator inhibitor-1 inhibitor |
US14/307,149 Division US20140296256A1 (en) | 2009-03-31 | 2014-06-17 | Plasminogen activator inhibitor-1 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010113022A1 true WO2010113022A1 (ja) | 2010-10-07 |
Family
ID=42827524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/000731 WO2010113022A1 (ja) | 2009-03-31 | 2010-03-31 | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8785473B2 (ja) |
EP (2) | EP2415755A4 (ja) |
JP (1) | JP5730190B2 (ja) |
KR (1) | KR101762574B1 (ja) |
CN (1) | CN102378753B (ja) |
AU (3) | AU2010231058A1 (ja) |
BR (1) | BRPI1013392A2 (ja) |
CA (1) | CA2757615C (ja) |
DK (1) | DK2607348T3 (ja) |
ES (1) | ES2874063T3 (ja) |
WO (1) | WO2010113022A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
WO2014171464A1 (ja) | 2013-04-15 | 2014-10-23 | 株式会社レナサイエンス | Pai-1阻害剤の新規用途 |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9447028B2 (en) | 2009-09-01 | 2016-09-20 | King's College London | Therapeutic aryl-amido-aryl compounds and their use |
JP2019520359A (ja) * | 2016-06-22 | 2019-07-18 | フーダン ユニヴァーシティFudan University | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 |
WO2021066062A1 (ja) | 2019-09-30 | 2021-04-08 | 株式会社レナサイエンス | 免疫チェックポイント分子の発現抑制剤 |
WO2021235532A1 (ja) | 2020-05-20 | 2021-11-25 | 株式会社レナサイエンス | 線溶系亢進薬、及びその用途 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3013796T3 (da) * | 2013-06-27 | 2020-03-16 | Lg Chemical Ltd | Biarylderivater som gpr120-agonister |
WO2015094912A1 (en) * | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Dimethylbenzoic acid compounds |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US10662183B2 (en) | 2014-11-07 | 2020-05-26 | The Regents Of The University Of Michigan | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same |
CN107522634B (zh) * | 2016-06-22 | 2020-09-01 | 复旦大学 | 联芳基脲类羧酸衍生物或其盐及其制备方法和用途 |
WO2018107707A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
CN110167583A (zh) * | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
EA201992386A1 (ru) | 2017-04-10 | 2020-03-27 | Байер Акциенгезельшафт | Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды и их применение |
WO2019018185A1 (en) | 2017-07-15 | 2019-01-24 | Arisan Therapeutics Inc. | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS |
CA3115981A1 (en) * | 2018-10-15 | 2020-04-23 | Gero Discovery Limited Liability Company | Pfkfb3 inhibitors and their uses |
EP3662908A1 (en) * | 2018-12-04 | 2020-06-10 | Consejo Superior de Investigaciones Cientificas (CSIC) | Modulating compounds of kchip2 and its use for the treatment of cardiovascular pathologies |
CN109970593B (zh) * | 2019-03-14 | 2019-11-08 | 北京工商大学 | 一种燕麦提取物的提取方法及其提取物和应用 |
BR112021018303A2 (pt) * | 2019-03-15 | 2021-11-23 | Massachusetts Gen Hospital | Novos inibidores de pequenas moléculas de fatores de transcrição tead |
CN115197117B (zh) * | 2022-05-17 | 2023-09-15 | 沈阳化工大学 | 抑制金黄色葡萄球菌胱硫醚-γ-裂解酶的吲哚类衍生物 |
KR20240054851A (ko) * | 2022-10-19 | 2024-04-26 | 이화여자대학교 산학협력단 | 티플락스티닌을 포함하는 복막 섬유증의 개선, 예방 또는 치료용 조성물 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120352A1 (de) * | 1983-03-09 | 1984-10-03 | BASF Aktiengesellschaft | N-Acyl-anthranilsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses |
JPH02256667A (ja) * | 1988-12-27 | 1990-10-17 | Masatoshi Yamato | 縮合キノリン系化合物およびその製造方法 |
JPH07196656A (ja) * | 1993-12-06 | 1995-08-01 | Merck Patent Gmbh | イミダゾピリジン |
JP2000503308A (ja) * | 1996-01-19 | 2000-03-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | キノリン―2―(1h)―オン類 |
JP2007502264A (ja) * | 2003-08-14 | 2007-02-08 | スミスクライン・ビーチャム・コーポレイション | Hm74a受容体アゴニストとしての2−置換安息香酸誘導体 |
WO2007083689A1 (ja) * | 2006-01-19 | 2007-07-26 | Renascience Co., Ltd. | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
JP2008502699A (ja) * | 2004-06-14 | 2008-01-31 | セプラコール・インコーポレイテッド | 肺疾患治療方法、及びそのための組成物 |
WO2009013915A1 (ja) | 2007-07-25 | 2009-01-29 | Renascience Co., Ltd. | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
WO2009123241A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS567716A (en) | 1979-07-03 | 1981-01-27 | Chugai Pharmaceut Co Ltd | Preventive and remedy for cerebral angiospasm |
AU3239393A (en) * | 1991-12-12 | 1993-07-19 | Scios Nova Inc. | Fluorenyl derivatives and their use as anti-inflammatory agents |
FR2790756B1 (fr) | 1999-03-11 | 2001-04-13 | Oreal | Nouveaux composes de la famille des benzylaminodiacetamides, compositions les comprenant, procede de preparation et utilisations |
WO2002098839A1 (fr) | 2001-06-01 | 2002-12-12 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamides et procede de preparation de ceux-ci |
AU2003273179A1 (en) | 2002-05-10 | 2003-12-12 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
US20050113450A1 (en) * | 2002-08-23 | 2005-05-26 | Atli Thorarensen | Antibacterial agents |
WO2005026127A1 (ja) | 2003-09-11 | 2005-03-24 | Institute Of Medicinal Molecular Design. Inc. | プラスミノゲンアクチベータインヒビター-1阻害剤 |
US20120178697A9 (en) | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US20050124667A1 (en) | 2003-10-30 | 2005-06-09 | Eric Sartori | Oxamide inhibitors of plasminogen activator inhibitor-1 |
US20050143384A1 (en) * | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
JP2005275352A (ja) | 2004-02-26 | 2005-10-06 | Konica Minolta Medical & Graphic Inc | ハロゲン化銀カラー感光材料及び面積階調画像形成方法 |
DE602005019316D1 (en) | 2004-11-24 | 2010-03-25 | Lilly Co Eli | Aromatische etherderivate als thrombin-hemmer |
MX2007006790A (es) | 2004-12-07 | 2007-08-15 | Toyama Chemical Co Ltd | Novedosos derivado de acido antranilico o sal del mismo. |
CA2613522A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
JP2007022943A (ja) | 2005-07-13 | 2007-02-01 | Dai Ichi Seiyaku Co Ltd | スクアレン合成酵素阻害薬 |
EP1764096A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel phloroglucinol derivatives having selectin ligand activity |
US20080139534A1 (en) | 2006-12-07 | 2008-06-12 | Xavier University Of Louisiana | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis |
JP2010120852A (ja) | 2007-03-09 | 2010-06-03 | Daiichi Sankyo Co Ltd | 新規なジアミド誘導体 |
JP5735799B2 (ja) | 2007-04-06 | 2015-06-17 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | ゴナドトロピン放出ホルモン受容体拮抗薬およびそれに関連する方法 |
JP5383483B2 (ja) * | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
BRPI0813176A2 (pt) * | 2007-06-15 | 2014-12-30 | Mission Pharma Co | Moléculas e composições par ainibir fator edema e adenilil ciclase |
BRPI0819799A2 (pt) * | 2007-11-23 | 2015-05-26 | Leo Pharma As | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença |
CA2714414A1 (en) * | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
-
2010
- 2010-03-31 DK DK13001154.7T patent/DK2607348T3/da active
- 2010-03-31 CN CN201080015064.9A patent/CN102378753B/zh active Active
- 2010-03-31 CA CA2757615A patent/CA2757615C/en active Active
- 2010-03-31 AU AU2010231058A patent/AU2010231058A1/en not_active Abandoned
- 2010-03-31 EP EP10758123A patent/EP2415755A4/en not_active Withdrawn
- 2010-03-31 US US13/262,259 patent/US8785473B2/en active Active
- 2010-03-31 BR BRPI1013392A patent/BRPI1013392A2/pt not_active Application Discontinuation
- 2010-03-31 EP EP13001154.7A patent/EP2607348B8/en active Active
- 2010-03-31 ES ES13001154T patent/ES2874063T3/es active Active
- 2010-03-31 JP JP2011506826A patent/JP5730190B2/ja active Active
- 2010-03-31 KR KR1020117025656A patent/KR101762574B1/ko active IP Right Grant
- 2010-03-31 WO PCT/IB2010/000731 patent/WO2010113022A1/ja active Application Filing
-
2014
- 2014-06-17 US US14/307,149 patent/US20140296256A1/en not_active Abandoned
-
2016
- 2016-06-09 AU AU2016203847A patent/AU2016203847A1/en not_active Abandoned
-
2017
- 2017-12-01 AU AU2017268669A patent/AU2017268669B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120352A1 (de) * | 1983-03-09 | 1984-10-03 | BASF Aktiengesellschaft | N-Acyl-anthranilsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses |
JPH02256667A (ja) * | 1988-12-27 | 1990-10-17 | Masatoshi Yamato | 縮合キノリン系化合物およびその製造方法 |
JPH07196656A (ja) * | 1993-12-06 | 1995-08-01 | Merck Patent Gmbh | イミダゾピリジン |
JP2000503308A (ja) * | 1996-01-19 | 2000-03-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | キノリン―2―(1h)―オン類 |
JP2007502264A (ja) * | 2003-08-14 | 2007-02-08 | スミスクライン・ビーチャム・コーポレイション | Hm74a受容体アゴニストとしての2−置換安息香酸誘導体 |
JP2008502699A (ja) * | 2004-06-14 | 2008-01-31 | セプラコール・インコーポレイテッド | 肺疾患治療方法、及びそのための組成物 |
WO2007083689A1 (ja) * | 2006-01-19 | 2007-07-26 | Renascience Co., Ltd. | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
WO2009013915A1 (ja) | 2007-07-25 | 2009-01-29 | Renascience Co., Ltd. | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
WO2009123241A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社レナサイエンス | プラスミノーゲンアクチベーターインヒビター-1阻害剤 |
Non-Patent Citations (41)
Title |
---|
ALLISON A. ET AL.: "Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action", J AM SOC NEPHROL, vol. 17, 2006, pages 2999 - 3012 |
AM. J. PATHOL., vol. 164, no. 2, February 2004 (2004-02-01), pages 449 - 456 |
AM. J. PATHOL., vol. 172, no. 3, March 2008 (2008-03-01), pages 691 - 701 |
ANUPAM BASU ET AL., PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) FACILITATES RETINAL ANGIOGENESIS IN A MODEL OF OXYGEN-INDUCED RETINOPATHY IOVS, vol. 50, no. 10, October 2009 (2009-10-01), pages 4971 - 4981 |
ASHCORT ET AL., J. CLIN. PATHOL., vol. 41, 1988, pages 467 - 470 |
AYA N. ET AL., J. PATHOL., vol. 166, 1992, pages 289 - 295 |
D T EITZMAN ET AL., J. CLIN. INVEST., vol. 97, 1996, pages 232 - 237 |
DAN J, BELYEA D ET AL.: "Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma", ARCH OPHTHALMOL., vol. 123, no. 2, February 2005 (2005-02-01), pages 220 - 4 |
DAVID L. CRANDALL ET AL.: "Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1", ARTERIOSCLER. THROMB. VASC. BIOL., vol. 26, 2006, pages 2209 - 2215 |
DOUGLAS E. VAUGHAN ET AL.: "PAI-1 Antagonists: Predictable Indications and Unconventional Applications", CURRENT DRUG TARGETS, vol. 8, 2007, pages 962 - 970 |
EGELUND R ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 13077 - 13086 |
FABIEN MILLIAT ET AL.: "Essential Role of Plasminogen Activator Inhibitor Type-1 in Radiation Enteropathy", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 172, no. 3, March 2008 (2008-03-01), pages 691 - 701 |
HISASHI KOSAKA ET AL.: "Interferon-y is a therapeutic target molecule for prevention of postoperative adhesion formation", NATURE MEDICINE, vol. 14, no. 4, April 2008 (2008-04-01), pages 437 - 441 |
HUNJOO HA ET AL.: "The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases", NEPHROLOGY, vol. 5, April 2009 (2009-04-01), pages 203 |
J. CLIN. INVEST, vol. 97, 1996, pages 232 - 237 |
J. HEPATOL., vol. 31, no. 4, October 1999 (1999-10-01), pages 703 - 711 |
J. LAB. CLIN. MED., vol. 144, no. 2, August 2004 (2004-08-01), pages 69 - 77 |
JACOBSEN JS ET AL., PROC NATL ACAD SCI USA, vol. 105, no. 25, 16 June 2008 (2008-06-16), pages 8754 - 9 |
JACOBSEN JS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, no. 25, 2008, pages 8754 - 8759 |
JESSICA K DEVIN ET AL.: "Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice", JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 39, 2007, pages 9 - 16 |
JOHN A. SCHOENHARD ET AL.: "Plasminogen activator inhibitor-1 has a circadian rhythm in blind individuals", THROMB HAEMOST, vol. 98, 2007, pages 479 - 481 |
JORIS J T H ROELOFS ET AL.: "Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. Kidney International", VOL, vol. 75, 2009, pages 52 - 59 |
KIVIRIKKO ET AL., ANAL. BIOCHEM., vol. 19, 1967, pages 249 - 255 |
KOHARA ET AL., J. MED. CHEM., vol. 39, 1996, pages 5228 - 5235 |
KOJI MAEMURA ET AL.: "Circadian Rhythms in the CNS and Peripheral Clock Disorders: Role of the Biological Clock in Cardiovascular Diseases", J PHARMACOL SCI, vol. 103, 2007, pages 134 - 138 |
M. EREN ET AL.: "Reactive site- dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 5, 2007, pages 1500 - 1508 |
M. LASSILA ET AL.: "Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease", DIABETOLOGIA, vol. 50, 2007, pages 1315 - 1326 |
MATSUO, O. ET AL., HAEMOSTASIS, vol. 16, 1986, pages 43 - 50 |
MICHELLE K. ET AL.: "Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis", THROMB HAEMOST, vol. 91, 2004, pages 438 - 49 |
NOBORU HATTORI ET AL.: "Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice", J. CLIN. INVEST, vol. 106, 2000, pages 1341 - 1350 |
ONCOGENE, vol. 22, no. 28, 10 July 2003 (2003-07-10), pages 4389 - 4397 |
See also references of EP2415755A4 * |
SHUNYA MATSUO ET AL.: "Multifunctionality of PAI-1 in fibrogenesis: Evidence from obstructive nephropathy in PAI-1-overexpressing mice", KIDNEY INTERNATIONAL, vol. 67, 2005, pages 2221 - 2238 |
TAKASHI ODA ET AL.: "PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction", KIDNEY INTERNATIONAL, vol. 30, 2001, pages 587 - 596 |
THROMB. HAEMOST., vol. 93, no. 4, April 2005 (2005-04-01), pages 631 - 640 |
TRENDS CARDIOVASC. MED., vol. 14, no. 5, July 2004 (2004-07-01), pages 196 - 202 |
W. A. BORDER ET AL., J. CLIN. INVEST., vol. 112, 2003, pages 379 |
W. A. BORDER ET AL., KIDNEY INT., vol. 59, 2001, pages 246 |
Y HUANG ET AL.: "Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis", KIDNEY INTERNATIONAL, vol. 70, 2006, pages 515 - 522 |
YOSHIDA Y ET AL., NEPHRON, vol. 88, 2001, pages 24 - 29 |
YUKO SUZUKI ET AL.: "Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells", BLOOD, vol. 113, no. 2, January 2009 (2009-01-01), pages 470 - 478 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447028B2 (en) | 2009-09-01 | 2016-09-20 | King's College London | Therapeutic aryl-amido-aryl compounds and their use |
JP2013545810A (ja) * | 2010-12-16 | 2013-12-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US10092537B2 (en) | 2013-04-15 | 2018-10-09 | Renascience Co., Ltd. | Use for PAI-1 inhibitor |
JP5840324B2 (ja) * | 2013-04-15 | 2016-01-06 | 株式会社レナサイエンス | Pai−1阻害剤の新規用途 |
JPWO2014171464A1 (ja) * | 2013-04-15 | 2017-02-23 | 株式会社レナサイエンス | Pai−1阻害剤の新規用途 |
WO2014171464A1 (ja) | 2013-04-15 | 2014-10-23 | 株式会社レナサイエンス | Pai-1阻害剤の新規用途 |
JP2019520359A (ja) * | 2016-06-22 | 2019-07-18 | フーダン ユニヴァーシティFudan University | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 |
JP7092356B2 (ja) | 2016-06-22 | 2022-06-28 | フーダン ユニヴァーシティ | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 |
WO2021066062A1 (ja) | 2019-09-30 | 2021-04-08 | 株式会社レナサイエンス | 免疫チェックポイント分子の発現抑制剤 |
JP7420402B2 (ja) | 2019-09-30 | 2024-01-23 | 株式会社レナサイエンス | 免疫チェックポイント分子の発現抑制剤 |
WO2021235532A1 (ja) | 2020-05-20 | 2021-11-25 | 株式会社レナサイエンス | 線溶系亢進薬、及びその用途 |
JPWO2021235532A1 (ja) * | 2020-05-20 | 2021-11-25 | ||
JP7391400B2 (ja) | 2020-05-20 | 2023-12-05 | 株式会社レナサイエンス | 線溶系亢進薬、及びその用途 |
Also Published As
Publication number | Publication date |
---|---|
US20140296256A1 (en) | 2014-10-02 |
EP2607348B1 (en) | 2021-03-17 |
CA2757615A1 (en) | 2010-10-07 |
EP2415755A1 (en) | 2012-02-08 |
CN102378753A (zh) | 2012-03-14 |
KR20120006027A (ko) | 2012-01-17 |
AU2010231058A1 (en) | 2011-11-10 |
ES2874063T3 (es) | 2021-11-04 |
DK2607348T3 (da) | 2021-05-25 |
JPWO2010113022A1 (ja) | 2012-10-04 |
AU2010231058A2 (en) | 2011-12-01 |
CN102378753B (zh) | 2016-03-02 |
EP2415755A4 (en) | 2012-09-19 |
EP2607348B8 (en) | 2021-04-21 |
JP5730190B2 (ja) | 2015-06-03 |
EP2607348A2 (en) | 2013-06-26 |
EP2607348A3 (en) | 2013-10-16 |
AU2017268669B2 (en) | 2019-05-16 |
AU2016203847A1 (en) | 2016-06-30 |
CA2757615C (en) | 2018-07-17 |
KR101762574B1 (ko) | 2017-07-28 |
US20120022080A1 (en) | 2012-01-26 |
BRPI1013392A2 (pt) | 2016-03-29 |
US8785473B2 (en) | 2014-07-22 |
AU2017268669A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010113022A1 (ja) | プラスミノーゲンアクチベーターインヒビター-1阻害剤 | |
EP3357513B1 (en) | Pharmaceutical composition and application thereof | |
TW408102B (en) | Phenyl urea compounds and their use for the treatment of disease states medicated by the chemokine, Interleukin-8 (IL-8) | |
ES2601192T3 (es) | Nuevos compuestos nitrosos como donadores de nitroxilo y métodos de uso de los mismos | |
TW200825072A (en) | Soluble epoxide hydrolase inhibitors | |
JPS61263969A (ja) | アスコルビン酸誘導体含有製剤 | |
ES2929539T3 (es) | Sal formada por ácido 2-(1-aciloxipentil) benzoico mediante un aminoácido básico o aminoguanidina, método de preparación y usos de la misma | |
JPH02290841A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
JP2009007258A (ja) | Pai−1産生抑制作用を有する3−アニリノ−2−シクロアルケノン誘導体 | |
JP2020500204A (ja) | ピペリジン−2,6−ジオン誘導体及びクローン病の治療 | |
CN104592145B (zh) | 一种苯并氧化呋咱组蛋白去乙酰化酶抑制剂及其制备方法和应用 | |
CN103333134A (zh) | 2-(3-氰基-4-烷氧基)苯基-4-取代噻唑-5-甲酸类化合物、组合物及其制备方法和用途 | |
JP2019537561A (ja) | Idhpの冠状動脈アテローム性硬化症の予防及び治療のための薬物又は健康補助食品の調製における応用 | |
JPS5914007B2 (ja) | 4−トリフルオロメチル安息香酸誘導体を含有する医薬組成物 | |
Riaz et al. | Novel pyridine-2, 4, 6-tricarbohydrazide derivatives: Design, synthesis, characterization and in vitro biological evaluation as α-and β-glucosidase inhibitors | |
TW201010994A (en) | Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases | |
WO2020135569A1 (zh) | 乙二胺类化合物及其用途 | |
WO2004110449A1 (fr) | Aporphine et oxoaporphine et leur utilisation a des fins medicales | |
CN105669461B (zh) | 邻硝基咖啡酸苯乙酯及其制备方法和应用 | |
CN109776494A (zh) | 一种多靶点抗肿瘤活性的烟酰胺磷酸核糖转移酶氮芥类抑制剂及其制备与应用 | |
KR102646322B1 (ko) | 이소인돌 유도체 | |
BRPI0804764A2 (pt) | inibidores da alfa-glicosidades, composições farmacêuticas compreendendo os mesmos e processo para sua preparação | |
CN107652265B (zh) | 1-(哌啶-4-基)-2-苯并咪唑酮类化合物及其应用 | |
EP3733640A1 (en) | Phenylpropionate compound, preparation method for same, and applications thereof | |
CN103145673A (zh) | 黄豆苷元衍生物及其药学上可接受的盐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080015064.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10758123 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011506826 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2757615 Country of ref document: CA Ref document number: 13262259 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010758123 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117025656 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8440/DELNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010231058 Country of ref document: AU Date of ref document: 20100331 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1013392 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1013392 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110930 |